MELVILLE, NY–(Marketwired – September 18, 2014) – ITUS Corporation (“ITUS”) (ITUS), a company that builds and protects innovation, today announced that its wholly owned subsidiary, Secure Web Conference Corporation (“SWCC”), filed a patent infringement lawsuit in the U.S. District Court for the Eastern District of New York against Apple Inc., in connection with SWCC’s patented Key Based Web Conferencing Encryption technology. Apple’s FaceTime video service debuted in 2010, and has been available via hundreds of millions of devices including iPhones (since the fourth generation iPhone), iPads (since the iPad 2), iPod Touches (since the fourth generation iPod), and all Macintosh desktop and laptop computers running OSX or later.

Robert Berman, ITUS’s President and CEO stated, “Our company was a pioneer in developing and patenting encryption technologies that were originally used in devices sold to the U.S. military. We recognized the monetization potential of these patents when we joined the company, and this lawsuit is the next step in realizing that potential.”

SWCC has already licensed the encryption patents to Logitech in connection with its LifeSize web conferencing service, and has a patent infringement lawsuit pending against Microsoft Corporation in connection with the SKYPE and Lync web conferencing services. A claims construction, or Markman hearing, in the Microsoft lawsuit is scheduled for September 23.

About ITUS Corporation

ITUS develops and acquires patented technologies for the purposes of patent monetization and patent assertion. The company currently has 10 patent portfolios in the areas of Key Based Web Conferencing Encryption, Encrypted Cellular Communications, E-Paper® Electrophoretic Display, Nano Field Emission Display (“nFED”), Micro Electro Mechanical Systems Display (“MEMS”), Loyalty Conversion Systems, J-Channel Window Frame Construction, VPN Multicast Communications, Internet Telephonic Gateway, and Enhanced Auction Technologies. Additional information is available at www.ITUScorp.com.

HAIFA, Israel, Sept. 16, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today it is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded (PLX) cell therapies in Japan.

Recent changes in Japan’s laws governing regenerative medicine and the approval of stem cell therapies indicate the country may now offer the fastest track to commercialization in the world for regenerative medicine treatments. As part of Pluristem’s strategy in Japan, on September 16, 2014, Company executives presented to a group of Japanese pharmaceutical executives in Tokyo, and conducted a series of one-on-one meetings with Japanese companies exploring a potential partnership with Pluristem.

To support its strategy in Japan, Pluristem is working with The Sage Group, a consulting firm specializing in healthcare industry transactions and business strategy, and Sage’s partner Waterfield HealthCom, a Japan-based firm managed by Yoshi Mizuta. Mr. Mizuta is a highly experienced pharmaceutical industry executive with more than 40 years in the business of financial healthcare transactions in the Japanese arena.

Japan’s government passed a bill in 2013, which goes into effect in November of this year, effectively fast-tracking the approval of stem cell therapies for marketing. According to the law, stem cell regenerative medicine therapies can receive conditional, time-limited approval for marketing, and be eligible for reimbursement, upon proof of safety but prior to verification of efficacy; safety and effectiveness need to be confirmed after the conditional approval.

Waterfield HealthCom’s Mr. Mizuta commented, “With its broad portfolio of indications and its commercial scale 3D cell manufacturing capabilities, Pluristem is a very desirable partner for Japanese pharmaceutical companies looking to bring cell therapies to the market in the near term.”

“As a result of Japan’s favorable new law, cell therapies like Pluristem’s PLX cells can receive market approval in Japan upon completion of Phase II trials when good safety and efficacy data is available. This could potentially reduce approval time down to two or three years,” Mr. Mizuta concluded.

Pluristem CEO Zami Aberman added, “The opportunity in Japan opens an accelerated path for the global regenerative medicine industry to prove the efficacy of cell therapies in a broad patient population in Japan. Japan has one of the most advanced healthcare systems, and the second largest healthcare market in the world.”

Pluristem currently has co-development and out-licensing partnership agreements with United Therapeutics (UTHR) and South-Korea-based CHA Bio&Diostech (CHA).

PETACH TIKVA, Israel, Sept. 17, 2014 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, “New Drugs and Treatment Targets in Psoriasis,” published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company’s CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.

The article states that biologics for the treatment of psoriasis are costly, require repeated injections, and some patients experience a loss of therapeutic effect. Thus, the development of orally available, small molecule drugs are desirable, state the article’s authors. They identify A3 adenosine receptor (A3AR) agonists as one of four potential small molecules currently in clinical trials.

The article includes a summary of Can-Fite’s Phase II psoriasis trial and includes CF101 among four small molecule drugs under development including Pfizer’s Tofacitinib, Celgene’s Apremilast, and Incyte’s Ruxolitinib.

“There is a need for small molecule orally bioavailable drugs for the treatment of psoriasis which is a chronic disease. We believe the good safety and efficacy profile that has been described in the Phase II and Phase II/III interim analysis, positions CF101 as a leading drug under development for this disease,” stated Dr. Pnina Fishman, CEO of Can-Fite.

Can-Fite’s Phase II/III psoriasis trial is ongoing with top line results expected to be released in the first quarter of 2015. The psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data.

MELVILLE, NY–(Marketwired – September 16, 2014) – ITUS Corporation (“ITUS”) (ITUS), a company that builds and protects innovation, today announced that its wholly owned subsidiary, J-Channel Industries Corporation (“JCIC”), has entered into a license agreement with Jeld-Wen, Inc., in connection with JCIC’s patented J-Channel Window Frame Construction technology.

Robert Berman, ITUS’s President and CEO stated, “In the past 7 days alone, we have entered into 5 revenue producing license agreements, and launched our seventh patent assertion program against eBay and the Alibaba companies. It’s amazing to see our talented team reunite, and so quickly rekindle the spark that leads to success. The momentum is beginning to build, good things are happening, and it’s an exciting time for our company and its shareholders.”

The Jeld-Wen agreement is the 12th settlement for the J-Channel Window Frame Construction technology, and resolves the patent infringement lawsuit filed against Jeld-Wen and Lowe’s on August 7, 2013, which will be dismissed.

About ITUS Corporation
ITUS develops and acquires patented technologies for the purposes of patent monetization and patent assertion. The company currently has 10 patent portfolios in the areas of Key Based Web Conferencing Encryption, Encrypted Cellular Communications, E-Paper® Electrophoretic Display, Nano Field Emission Display (“nFED”), Micro Electro Mechanical Systems Display (“MEMS”), Loyalty Conversion Systems, J-Channel Window Frame Construction, VPN Multicast Communications, Internet Telephonic Gateway, and Enhanced Auction Technologies. Additional information is available at www.ITUScorp.com.